Michael Tarvin compensation by year
SELECT MEDICAL Summary Compensation Table · all 5 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Salary | $520,000 | $520,000 | $520,000 | $520,000 | $520,000 |
| Bonus | $0 | $0 | $0 | — | — |
| Stock awards | $1,677,000 | $1,619,000 | $3,172,800 | $2,971,000 | $2,992,000 |
| Option awards | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $1,040,000 | $1,040,000 | $1,040,000 | $0 | $790,400 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $5,845 | $5,707 | $115,775 | $148,448 | $141,285 |
| Total | $3,242,845 | $3,184,707 | $4,848,575 | $3,639,448 | $4,443,685 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SELECT MEDICAL HOLDINGS CORP DEF 14A filed March 15, 2024, accession 0001104659-24-034799, and prior-year filings. Open the filing on EDGAR.
How this page was built: the SELECT MEDICAL HOLDINGS CORP filed document, accession 0001104659-24-034799. Every figure is read from that document and cited to the page and table it appears in. Filed March 15, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 100,000 | $2,350,000 | — |
| RSU | 80,000 | $1,880,000 | — |
| RSU | 66,666 | $1,566,651 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in SELECT MEDICAL HOLDINGS CORP's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2023 proxy (filed March 15, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-08-01 | Tax withholding | — | 19,640 | $12.57 | 508,120 |
| 2025-07-29 | Grant or award | — | 100,000 | $0.00 | 527,760 |
| 2025-04-30 | Tax withholding | — | 9,034 | $18.24 | 427,760 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
SELECT MEDICAL’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Robert Ortenzio | Executive Chairman and Co-Founder | $10,771,792 |
| David Chernow | Chief Executive Officer (Principal Executive Officer) | $10,706,265 |
| Rocco Ortenzio | Vice Chairman and Co-Founder | $7,083,521 |
| Martin Jackson | Senior Executive Vice President of Strategic Finance and Operations | $6,468,839 |
| Michael Tarvin · this page | Senior Executive Vice President, General Counsel and Secretary | $4,443,685 |
| Michael Malatesta | Executive Vice President and Chief Financial Officer (Principal Financial Officer) | $1,526,244 |
The full SELECT MEDICAL compensation record
free company briefThis page is one person within SELECT MEDICAL's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SELECT MEDICAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.